F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comRubicon Research Limited is a fast-growing pharmaceutical company known for its strong research and development (R&D) capabilities and innovative product portfolio. The company specializes in developing differentiated formulations for global markets and has established partnerships with several multinational pharma firms.
In this article, we’ll explore Rubicon Research Ltd’s share price target from 2025 to 2030, along with its business profile, financial highlights, and future investment potential.
| Detail | Value |
|---|---|
| Open | ₹598.80 |
| Previous Close | ₹600.15 |
| Day’s High | ₹599.65 |
| Day’s Low | ₹570.75 |
| VWAP | ₹582.40 |
| Volume | 788,455 |
| Value (Lacs) | ₹4,551.36 |
| Market Cap (Cr.) | ₹9,510 |
| Beta (Volatility) | 1.58 |
| 52-Week High | ₹639.00 |
| 52-Week Low | ₹570.75 |
| Face Value | ₹1 |
| Book Value per Share | ₹40.60 |
| UC Limit | ₹720.15 |
| LC Limit | ₹480.15 |
| All-Time High | ₹639.00 |
| All-Time Low | ₹570.75 |
Rubicon Research Limited is a pharmaceutical product development company focused on complex generics, specialty pharmaceuticals, and lifecycle management products. Headquartered in Mumbai, Rubicon operates globally with facilities approved by the USFDA and other major regulatory authorities.
The company offers end-to-end solutions from product conceptualization to commercial manufacturing and has a diversified portfolio across therapeutic areas such as pain management, dermatology, and cardiovascular care.
USFDA-approved facilities with global client base.
Strong R&D focus driving product innovation.
Diversified presence in complex generics and specialty formulations.
Rapidly growing domestic and export business.
Increasing institutional participation and strong promoter holding.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 59.99% |
| Retail & Others | 22.71% |
| Foreign Institutions | 9.37% |
| Mutual Funds | 5.63% |
| Other Domestic Institutions | 2.30% |
The shareholding data shows a dominant promoter presence and healthy institutional participation, which reflects strong market confidence in the company’s growth potential.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 610 | 640 |
| 2026 | 660 | 720 |
| 2027 | 750 | 810 |
| 2028 | 820 | 880 |
| 2029 | 900 | 970 |
| 2030 | 1,000 | 1,080 |
These projections are based on Rubicon’s business expansion, product launches, regulatory approvals, and financial performance trends in the pharmaceutical sector.
Rubicon Research’s share price in 2025 is expected to show moderate growth as the company strengthens its domestic formulations business and enhances R&D capabilities.
Why?
Expanding product portfolio in high-demand therapeutic areas.
Regulatory approvals in new markets like the US and EU.
Increased institutional interest due to strong promoter confidence.
Investment Advice: Good time for accumulation; ideal for medium-term investors.
In 2026, Rubicon Research is expected to deliver stronger growth driven by global partnerships and increased exports.
Why?
Entry into new international markets.
Improved margins from high-value specialty products.
R&D-driven revenue expansion.
Investment Advice: Hold for long-term growth; strong potential in the pharma innovation segment.
Rubicon may see a significant price surge in 2027 due to consistent product launches and potential collaboration with multinational firms.
Why?
Robust R&D pipeline materializing into commercial success.
Possible acquisitions or strategic alliances.
Improved return ratios and balance sheet strength.
Investment Advice: Reinvest profits; promising year for long-term investors.
The company’s fundamentals are expected to improve further by 2028 as it scales up production and exports.
Why?
Efficient cost management and margin improvement.
New patent filings and product approvals.
Enhanced brand visibility in regulated markets.
Investment Advice: Continue SIPs; expect steady CAGR growth.
By 2029, Rubicon Research could become a major player in the mid-cap pharma space, benefiting from its strong R&D foundation.
Why?
Consistent earnings growth.
Expansion in the US generics and specialty market.
Strong demand from export markets.
Investment Advice: Hold for compounding returns; ideal for long-term investors.
By 2030, Rubicon Research is expected to achieve new milestones in revenue and profitability, reflecting its innovation-led strategy.
Why?
Diversified revenue streams across geographies.
Sustained R&D investment.
Strong management and operational excellence.
Investment Advice: Excellent long-term investment for those seeking exposure to the pharma sector.
Yes. Rubicon Research Ltd has shown consistent progress in both domestic and international markets. With its strong R&D base, rising institutional interest, and focus on innovation, it holds significant potential for long-term investors.
Strong promoter holding (59.99%) ensuring management stability.
Expanding presence in global regulated markets.
Robust product pipeline.
Increasing profitability potential.
Regulatory delays in product approvals.
Market volatility due to global pharma pricing pressure.
Competition from large-cap pharmaceutical companies.
Rubicon Research Ltd is emerging as one of the promising mid-cap pharmaceutical companies in India. With a current price near ₹600 and consistent growth potential, analysts believe the stock could reach ₹1,000–₹1,080 by 2030.
Its focus on innovation, expansion in international markets, and solid R&D capabilities make it a strong contender for long-term portfolios. Investors seeking steady growth in the healthcare sector can consider Rubicon Research as a reliable pick for the coming decade.
1. What is the current share price of Rubicon Research Ltd?
As of October 25, 2025, the share price is around ₹600 on NSE.
2. What is the share price target for Rubicon Research in 2025?
The 2025 target is between ₹610 and ₹640.
3. What is Rubicon Research’s market capitalization?
Its current market cap is approximately ₹9,510 crore.
4. What is Rubicon Research’s 52-week high and low?
The 52-week high is ₹639.00, and the low is ₹570.75.
5. What is the promoter holding in Rubicon Research?
Promoters hold 59.99% of the company’s shares.
6. Is Rubicon Research a good stock to buy?
Yes, it’s a good long-term investment due to strong fundamentals and R&D-driven growth.
7. What is Rubicon Research’s Beta value?
The Beta is 1.58, indicating higher volatility than the overall market.
8. What is the book value per share of Rubicon Research?
The book value per share stands at ₹40.60.
9. Is Rubicon Research suitable for long-term investment?
Yes, it offers solid long-term growth potential given its expansion and innovation strategy.
10. What is the future outlook of Rubicon Research?
The future looks promising as the company focuses on product innovation, global partnerships, and operational expansion.
Disclaimer: This article is for educational and informational purposes only. Investors should consult certified financial advisors before making any investment decisions.
Register & Login